Tempest Therapeutics Buy Rating Reaffirmed at HC Wainwright
| TPST Stock | USD 6.55 0.24 3.53% |
Slightly above 60% of Tempest Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tempest Therapeutics suggests that many traders are alarmed. Tempest Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tempest Therapeutics' earnings reports, geopolitical events, and overall market trends.
HC Wainwright reissued their buy rating on shares of Tempest Therapeutics in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a 47.00 price target on the stock. Separately, Piper Sandler restated an overweight rating and issued a 8.00 price objective on shares of Tempest Therapeutics
Read at thelincolnianonline.com
 |
Tempest Therapeutics Fundamental Analysis
We analyze Tempest Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tempest Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tempest Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Tempest Therapeutics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Tempest Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tempest Therapeutics stock to make a market-neutral strategy. Peer analysis of Tempest Therapeutics could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics with similar companies.
Peers
Tempest Therapeutics Related Equities
| FBRX | Forte Biosciences | 11.76 | ||||
| ARMP | Armata Pharmaceuticals | 9.23 | ||||
| IKNA | Ikena Oncology | 1.75 | ||||
| SANA | Sana Biotechnology | 1.11 | ||||
| RVMD | Revolution Medicines | 1.18 | ||||
| OLMA | Olema Pharmaceuticals | 1.68 | ||||
| LYEL | Lyell Immunopharma | 2.50 | ||||
| RNXT | RenovoRx | 2.83 | ||||
| AKTX | Akari Therapeutics | 3.57 | ||||
| PCSA | Processa Pharmaceuticals | 4.17 | ||||
| INDP | Indaptus Therapeutics | 4.55 | ||||
| RZLT | Rezolute | 4.90 | ||||
| ANEB | Anebulo Pharmaceuticals | 5.77 | ||||
| ZNTL | Zentalis Pharmaceuticals | 6.20 | ||||
| CGEM | Cullinan Oncology | 6.43 | ||||
| GLUE | Monte Rosa | 8.42 |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.